These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

496 related items for PubMed ID: 9563896

  • 21. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
    Morgan SE, Cadena RS, Raimondi SC, Beck WT.
    Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
    [Abstract] [Full Text] [Related]

  • 22. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
    Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, Piccart MJ.
    Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526
    [Abstract] [Full Text] [Related]

  • 23. Topoisomerase IIalpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia.
    Uggla B, Tina E, Nahi H, Paul C, Höglund M, Sirsjö A, Tidefelt U.
    Int J Oncol; 2007 Jul; 31(1):153-60. PubMed ID: 17549416
    [Abstract] [Full Text] [Related]

  • 24. Drastic reduction of topoisomerase II alpha associated with major acquired resistance to topoisomerase II active agents but minor perturbations of cell growth.
    Hashimoto S, Chatterjee S, Ranjit GB, Bao C, Ford J, Ganapathi R, Berger SJ, Berger NA.
    Oncol Res; 1995 Jul; 7(7-8):407-16. PubMed ID: 8747604
    [Abstract] [Full Text] [Related]

  • 25. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
    Davis PL, Shaiu WL, Scott GL, Iglehart JD, Hsieh TS, Marks JR.
    Anticancer Res; 1998 Jul; 18(4C):2919-32. PubMed ID: 9713486
    [Abstract] [Full Text] [Related]

  • 26. Role of HER2 gene overexpression in breast carcinoma.
    Ménard S, Tagliabue E, Campiglio M, Pupa SM.
    J Cell Physiol; 2000 Feb; 182(2):150-62. PubMed ID: 10623878
    [Abstract] [Full Text] [Related]

  • 27. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
    Khélifa T, René B, Le Mée S, Lambert B, Saucier JM, Markovits J, Jacquemin-Sablon H, Jacquemin-Sablon A.
    Cancer Res; 1999 Oct 01; 59(19):4927-36. PubMed ID: 10519406
    [Abstract] [Full Text] [Related]

  • 28. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
    Lyne JC, Melhem MF, Finley GG, Wen D, Liu N, Deng DH, Salup R.
    Cancer J Sci Am; 1997 Oct 01; 3(1):21-30. PubMed ID: 9072304
    [Abstract] [Full Text] [Related]

  • 29. Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process.
    Whitacre CM, Zborowska E, Gordon NH, Mackay W, Berger NA.
    Cancer Res; 1997 Apr 15; 57(8):1425-8. PubMed ID: 9108439
    [Abstract] [Full Text] [Related]

  • 30. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
    Depowski PL, Rosenthal SI, Brien TP, Stylos S, Johnson RL, Ross JS.
    Mod Pathol; 2000 May 15; 13(5):542-7. PubMed ID: 10824926
    [Abstract] [Full Text] [Related]

  • 31. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
    Koshiyama M, Fujii H, Kinezaki M, Morita Y, Nanno H, Yoshida M.
    Anticancer Res; 2001 May 15; 21(4B):2925-32. PubMed ID: 11712788
    [Abstract] [Full Text] [Related]

  • 32. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K, Petersen BO, Falck J, Helin K, Jensen PB, Sehested M.
    Clin Cancer Res; 2000 Apr 15; 6(4):1488-97. PubMed ID: 10778981
    [Abstract] [Full Text] [Related]

  • 33. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
    Xu FJ, Stack S, Boyer C, O'Briant K, Whitaker R, Mills GB, Yu YH, Bast RC.
    Clin Cancer Res; 1997 Sep 15; 3(9):1629-34. PubMed ID: 9815853
    [Abstract] [Full Text] [Related]

  • 34. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line.
    Son YS, Suh JM, Ahn SH, Kim JC, Yi JY, Hur KC, Hong WS, Muller MT, Chung IK.
    Cancer Chemother Pharmacol; 1998 Sep 15; 41(5):353-60. PubMed ID: 9523730
    [Abstract] [Full Text] [Related]

  • 35. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer.
    Dingemans AM, Witlox MA, Stallaert RA, van der Valk P, Postmus PE, Giaccone G.
    Clin Cancer Res; 1999 Aug 15; 5(8):2048-58. PubMed ID: 10473085
    [Abstract] [Full Text] [Related]

  • 36. Regulation of p38 phosphorylation and topoisomerase IIalpha expression in the B-cell lymphoma line Jiyoye by CD26/dipeptidyl peptidase IV is associated with enhanced in vitro and in vivo sensitivity to doxorubicin.
    Yamochi T, Yamochi T, Aytac U, Sato T, Sato K, Ohnuma K, McKee KS, Morimoto C, Dang NH.
    Cancer Res; 2005 Mar 01; 65(5):1973-83. PubMed ID: 15753397
    [Abstract] [Full Text] [Related]

  • 37. Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer.
    Järvinen TA, Kononen J, Pelto-Huikko M, Isola J.
    Am J Pathol; 1996 Jun 01; 148(6):2073-82. PubMed ID: 8669491
    [Abstract] [Full Text] [Related]

  • 38. Structural and functional analysis of the control region of the human DNA topoisomerase II alpha gene in drug-resistant cells.
    Takano H, Ise T, Nomoto M, Kato K, Murakami T, Ohmori H, Imamura T, Nagatani G, Okamoto T, Ohta R, Furukawa M, Shibao K, Izumi H, Kuwano M, Kohno K.
    Anticancer Drug Des; 1999 Apr 01; 14(2):87-92. PubMed ID: 10405635
    [Abstract] [Full Text] [Related]

  • 39. Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation.
    Aigner A, Juhl H, Malerczyk C, Tkybusch A, Benz CC, Czubayko F.
    Oncogene; 2001 Apr 19; 20(17):2101-11. PubMed ID: 11360194
    [Abstract] [Full Text] [Related]

  • 40. Interference with topoisomerase IIalpha potentiates melphalan cytotoxicity.
    Hirota H, Gosky D, Berger NA, Chatterjee S.
    Int J Oncol; 2002 Feb 19; 20(2):311-8. PubMed ID: 11788894
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.